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Abstract
Over-the-counter antiaging formulations aim to prevent or 
minimize the signs of aging skin, and to maintain the benefits 
obtained from different cosmetic procedures. Even though a 
huge selection of such products is available on the market, 
evidence and good clinical practice of the data supporting 
their use are oftentimes lacking. In this systematic review, the 
authors reviewed scientific data available in the published 
literature on the most common ingredients used in antiaging 
cosmetics, with a particular focus on in vivo studies. 
© 2020 S. Karger AG, Basel
Introduction
During the past years, research on cutaneous aging 
mechanisms has gained considerable importance. This is 
due to various reasons – on the one hand, understanding 
aging mechanisms is crucial for the development of new 
lifestyle and beauty products, on the other hand, the skin 
is attracting considerable attention as an indicator of the 
health status of internal organs [1]. 
Skin aging is a complex biological process, from birth 
onwards, though the first signs of skin aging are usually 
noticeable only in the late twenties. It is based on a com-
plex interplay between proinflammatory factors of the 
environment, lifestyle, and intra-individual genetics. 
With aging, cell activity decreases at a molecular level; 
collagen production reduces, and nonfunctional elastic 
fibers increase [2, 3]. 
At the center of this process are the so-called free oxy-
gen radicals, also known as reactive oxygen species (ROS), 
which promote the aging process of the skin [1]. ROS 
damage of cellular structures such as the DNA or lipid 
membranes, which leads to upregulation of matrix metal-
loproteinases (especially MMP1 and MMP2) in fibro-
blasts; hence, increased breakdown and reduced build-up 
of collagen and elastin [4]. 
While very little is known about the role of genetics in 
intrinsic skin aging, or about its potential to influence in-
trinsic factors (apart from healthy nutrition and lifestyle), 
extrinsic skin aging occurs mainly due to the cumulative 
exposure to ultraviolet radiation [5]. Therefore, the best 










































































A vast array of cosmeceuticals is available on the mar-
ket to reduce signs of skin aging. These cosmetic products 
claim to have biologically active ingredients with medici-
nal or drug-like benefits. Evidence and good clinical prac-
tice of the data supporting their use are often lacking. This 
article reviews the evidence available in the published lit-
erature which supports the use of ingredients most com-
monly used in cosmeceuticals, with a special focus on in 
vivo studies. 
Materials and Methods




Retinoids are natural or synthetic derivates of vitamin 
A. The naturally occurring vitamin A (retinol) is oxidized 
reversibly to retinaldehyde, which in turn is oxidized ir-
reversibly to the biologically active form – retinoic acid 
(tretinoin) [6]. 
Retinoids have been applied topically and systemically 
to treat skin diseases – in particular acne vulgaris – since 
the 1940s. Their antiaging effect has been propagated 
since the 1980s [7].
The antiaging-specific mechanism of action is based 
on its interaction with the retinoic acid receptor in the 














    -  No studies in humans
    -  No in vitro studies
    -  No prospective or retrospective studies 
Excluded: did not examine topical antiaging agents 
Studies included: 59
Articles screened on the basis of the abstract: 509



















Fig. 1. Flowchart of the Materials and Methods flow diagram of the search and selection process according to 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis. AHA, α-hydroxy acids; HA, hyaluronic 
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Table 1. Human studies on topical retinoids [10, 74–87]





R, DB, PC,  
PG
120 4 randomized groups of 30 subjects receiving 
either (1) 0.04% retinol, (2) 1% melibiose + 4% 
lactose, (3) 0.04% retinol + 1% melibiose + 4% 
lactose, or (4) 1% salicylic acid
Significant differences in efficacy and lingering activity assessed by Cutometer 
and image analysis after optical shadowing
Varani 
et al. [75]
PC, RL 53 1% topical retinol vs. vehicle control Statistically significant histological improvement on day 7 (increase in fibroblast 




R, DB, PC,  
RL
36 Topical 0.4% retinol lotion vs. its vehicle up to 3 
times/week for 24 weeks
Significant differences between retinol- and vehicle-treated skin in fine wrinkle 
scores (p < 0.001); retinol treatment significantly increased glycosaminoglycan 
expression (p = 0.02) and procollagen I immunostaining (p = 0.049)
Kang 
et al. [77] 
R, DB, PG,  
PC
30 Topical retinol vs. retinoic acid vs. vehicle 
control
Retinol produced from none to only trace erythema, which was clinically and sta-
tistically insignificant, whereas retinoic acid induced a significant 3.7-fold increase 
in erythema score vs. vehicle (n = 10, p < 0.01); however, retinol induces epidermal 
thickening and enhances CRABP II and CRBP mRNA and protein expression 
Randhawa 
et al. [78]
R, DB, PC 62 Retinol formulation vs. its vehicle to full face for 
52 weeks 
The retinol group showed significant photodamage improvement over vehicle 
at all time points during the study; after 52 weeks, retinol had improved crow’s 
feet fine lines by 44%, and mottled pigmentation by 84%, with over 50% of 
subjects showing +2 grades of improvement in many parameters; additionally, 
at week 52, histochemical data confirmed the clinical results, showing increased 




R, PC, RL 229 0.5, 0.1, or 0.05% retinaldehyde for 1–3 months 
on one forearm and a vehicle control on the 
other
Significant dose-dependent increase in epidermal thickness/keratin 14 immuno-
reactivity; at a high concentration (0.5%), the morphological changes noted were 
similar to those induced by <0.1% topical retinoic acid; improved tolerance with 
decreasing concentration could be shown
Creidi 
et al. [10]
MC, DB, PC, 
PG 
125 Topical retinaldehyde (0.05%), retinoic acid 
(0.05%), or vehicle control for 44 weeks once per 
day 
Retinaldehyde and retinoic acid had similar improvements in profilometric 





MC, DB, PC 800 0.1% isotretinoin vs. vehicle cream applied on 
face, forearms, and hands
Statistically significant clinical improvement in wrinkling, pigmentation, 
sallowness, and texture on clinical evaluation 
Weinstein 
et al. [81]
MC, R, DB, 
PC
251 Topical tretinoin at 0.05% or 0.01% vs. vehicle 
control
Significant improvement in fine wrinkling, mottled hyperpigmentation, 
roughness, laxity, and epidermal thickness in the group treated with 0.05% 
tretinoin vs. 0.01% and vehicle groups; dose-dependent responses but no effect 
on dermal thickness, collagen regeneration, or reversal of keratinocyte atypia
Olsen 
et al. [82]
MC, R, DB, 
PC
298 Once daily application of either 0.05% or 0.01% 
tretinoin emollient cream vs. vehicle cream for a 
duration of 1 year
Significant improvement in histological and clinical markers in both the 0.05 
and 0.01% tretinoin group as compared with vehicle 
Leyden 
et al. [83]
R, DB, PC ? 0.05% tretinoin cream vs. vehicle control once 
daily in the treatment of photodamaged facial 
skin for 6 months
Significant amelioration of many signs of photodamage were achieved with mini-
mal side effects; fine and coarse wrinkling, sallowness, looseness, and hyperpig-
mentation were significantly improved with tretinoin therapy; an objective method 
based on digital image processing of silicone rubber casts obtained from the 
crow’s-feet area also indicated that the skin surface topography was smoother and 
less wrinkled in the tretinoin-treated group than the vehicle-control group 
Olsen 
et al. [84]
MC, R, DB, 
PC 
296 Tretinoin at 0.05, 0.01, or 0.001% in an emollient 
cream formulation vs. vehicle in the treatment of 
photodamaged facial skin for 24 weeks 
Tretinoin emollient cream 0.05% appears to be safe and effective in the 
treatment of photodamaged skin
Sendagorta 
et al. [85]
MC, R, PC 776 36 weeks of treatment with either vehicle cream 
or isotretinoin cream, applied once nightly
Treatment with isotretinoin resulted in statistically significant improvement in 
overall appearance, fine wrinkling, discrete pigmentation, sallowness, and 
texture; isotretinoin cream was well tolerated 
Ellis 
et al. [86]
R, SB, PC 30 4 months of treatment with topical tretinoin Statistically significant improvement in fine and coarse wrinkling and skin texture; 
the number of discrete lentigines decreased by 71% vs. before therapy; histologi-
cally, there was a statistically significant thickening of the epidermis; side effects 
were limited to a cutaneous retinoid reaction that diminished as therapy proceeded
Kang 
et al. [87]
MC, R, PC 204 Tretinoin vs. vehicle emollient cream applied to 
the entire face once a day for up to 2 years 
Long-term treatment with tretinoin emollient cream 0.05% is safe and effective 
in subjects with moderate-to-severe facial photodamage









































































tion in the dermis, keratinization of the epidermis, and 
inhibition of UV-induced MMP production [8]. Addi-
tionally, retinoids are able to inhibit tyrosinase, which re-
duces hyperpigmentation [9]. 
Various retinoids have been studied for the treatment 
of aging skin. Table 1 gives an overview of the clinical 
studies with good evidence of clinical and/or histological 
improvement in aging skin by retinoids. Precursor forms 
of tretinoin, such as retinol and retinaldehyde, are com-
monly used in cosmeceuticals. They were shown to have 
fewer side effects than tretinoin, the biologically active 
form. The latter has the best evidence to reduce signs of 
aging skin (Table 1). Tretinoin is only available on pre-
scription, as it can cause significant side effects such as 
erythema, xerosis, desquamation, and pruritus. Random-
ized trials have shown comparable antiaging effects of 
retinol and retinaldehyde compared to tretinoin [9, 10]. 
However, as retinol needs to be converted into tretinoin 
in vivo to become biologically active, it has been specu-
lated that retinol is 20-fold less effective than tretinoin 
[11]. Additionally, as retinol is extremely unstable and 
easily gets degraded on exposure to light and air, an ap-
propriate vehicle needs to be used in creams to elicit its 
efficacy [12]. 
α-Hydroxy Acids 
α-Hydroxy acids (AHAs) are widely used in chemical 
peeling and cosmetic formulations. There are several 
AHA types, with the most often used being glycolic, citric, 
lactic, pyruvic, mandelic, and tartaric acids [13].
Its exact mechanism of action has not yet been fully 
clarified. According to the literature, they increase the 
water retention capacity at the epidermal level, cause des-
quamation and softening, as well as normalization of the 
differentiation by influencing intracellular ion binding 
[14, 15]. At the level of the dermis, dose-dependent in-
creases in fibroblast proliferation, collagen production, 
and glycosaminoglycan synthesis have been described 
[16].
The beneficial effects were histologically proven in in-
dividual studies [17–19]. In these studies, clinical effects 
included increases in skin firmness and thickness, im-
provement in skin texture, and reduction in fine wrinkles. 
Hyaluronic Acid
Hyaluronic acid (HA), a nonsulfated glycosaminogly-
can, is composed of repeating units of polymeric disac-
charides of D-glucuronic acid and N-acetyl-D-glucos-
amine linked by a glucuronidic β (1→3) bond. It is wide-
ly used in esthetic medicine. Due to its structure, it has a 
remarkable water-holding ability. Consequently, it im-
proves tissue hydration. In addition, skin hydration and 
antioxidant effects of HA promote cell regeneration and 
stimulate the production of collagen [20].
The percutaneous absorption of HA, across the stra-
tum corneum, is dependent on its molecular weight. De-
pending on the chain length, it is categorized as small-size 
HA fragments (HAFs; < 50 kDa), intermediate-size HA 
fragments (HAFi; 50–400 kDa), and large-size HA frag-
ments (HAFl; > 400 kDa) [21].
Experimental studies have shown that topically ap-
plied HAFs and HAFi are able to penetrate the epidermis, 
but only HAFi were able to induce cellular proliferation 
within the epidermal and dermal compartments in vivo 
[21]. A vehicle-controlled study by Kaya et al. [21] showed 
histologically an increase in human skin thickness in re-
sponse to HAFi accompanied by a clear clinical improve-
ment in patients with skin atrophy. In contrast, the same 
concentration of HAFl and HAFs applied to the same pa-
tients had no effect on skin thickness. 
In another trial, 76 female patients with periocular 
wrinkles were administered a 0.1% cream formulation 
containing HA of different molecular weights twice daily 
for a period of 60 days. All HA-based creams demonstrat-
ed a significant improvement in skin hydration and over-
all elasticity values when compared to placebo. However, 
a significant reduction in wrinkle depth was only ob-
served in the women treated with a cream formulation 
containing low-molecular-weight HA (50 and 130 kDa) 
[22].
Additional human clinical studies on skin rejuvena-
tion by topically applied HA are listed in Table 2. 
Antioxidants
Substances with antioxidant activity find great appli-
cation in cosmeceuticals. Their effect is based on the neu-
tralization of free radicals (ROS), which are responsible 
for the degradation of collagen fibers. Most commonly 
applied antioxidants are vitamins, which are able to pen-
etrate the skin barrier due to their low molecular weight. 
Table 3 (antioxidants) gives an overview of the most pre-
cisely studied substances used in cosmeceuticals with an-
tioxidant properties. 
Niacinamide (Vitamin B3)
Niacinamide, also known as nicotinamide, is part of 
the niacin coenzymes NAD+, NADP+, and their reduced 
forms NADH and NADPH. Among others, these coen-
zymes play a role in DNA synthesis and repair. Surjana et 
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Table 2. Human studies on α-hydroxy acids and hyaluronic acid [17–19, 21, 88–97]
Study Study design n Treatment arm(s) Efficacy
α-Hydroxy acid: glycolic acid
Newman 
et al. [17]
R, DB, PC,  
RL 
41 Glycolic acid (50%) or vehicle was applied 
topically for 5 min to one side of the face, 
forearms, and hands, once weekly for 4 weeks; 
punch biopsies were taken before therapy and at 
5 weeks for histologic study 
Reduction in fine wrinkles and solar keratosis, improvement in skin texture; 
histologically reduction in corneal layer, epidermal thickening;
some samples show collagen thickening 
Thibault 
et al. [88]
R, DB, PC 75 5% glycolic acid cream vs. the placebo cream to 
the face and neck for a period of 3 months 
Overall, there was a trend toward greater improvement or less worsening in the 
glycolic acid group for all for photoaging clinically; statistically significant 
improvement favoring the active cream in general skin texture and 
discoloration, and a nonsignificant trend favoring glycolic acid in the reduction 
of wrinkles
α-Hydroxy acid: glycolic acid, lactic acid, citric acid
Ditre 
et al. [18]
R, PC, PG,  
RL 
17 Glycolic acid 25% (n = 5), lactic acid (n = 5), 
citric acid (n = 7) vs. placebo, application on 
forearms for 6 months 




R, DB, PC 74 Glycolic acid, L-lactic acid, or vehicle creams 
were applied twice daily to the face and outer 
aspect of the forearms for 22 weeks
More patients in the 8% glycolic acid or 8% L-lactic acid group improved at least 1 
grade (on a scale from 0 to 9) in overall photodamage severity on the face than in 
the vehicle group (76% glycolic acid, 71% lactic acid, and 40% vehicle; p < 0.05); 
on the forearms, after 22 weeks, treatment with glycolic acid was superior to the 
vehicle in improving the overall severity of photodamage and sallowness (p < 
0.05); L-lactic acid cream was significantly superior to the vehicle in reducing the 
overall severity of photodamage (p < 0.05), mottled hyperpigmentation (p < 0.05), 
sallowness (p < 0.05), and roughness on the forearms (p < 0.05) at week 22
Lactic acid
Smith [19] OL, PG 24 12% (n = 14) or 5% (n = 10) lactic acid test 
solutions twice a day to the full face, except the 
eyelids for 3 months 
Increased firmness and thickness of the epidermis and dermis; 





OL, PG 24 Mandelic acid (4 and 6%) applied topically to the 
face twice a day for 4 weeks 
Significant increase in skin firmness and elasticity of the lower eyelid 




SB, PC, RL 20 5% ALA on right half of the face and placebo gel 
on left half, twice daily for 6 months 
Mean epidermal thickness significantly increased on the verum side; mean dermal 
thickness increased more (nonsignificant) on the verum side vs. the placebo side
Beitner 
[92]
R, PC, DB,  
RL 
33 Half of the face treated with 5% ALA cream and 
other half with control cream, twice daily for 12 
weeks 




OL 15 5% ALA on the face twice daily for 12 weeks Overall, 50% reduction in facial lines; marked improvement in fine lines; 
improved texture and decreased discoloration 
Sherif 
et al. [94]
R, DB, PC,  
RL 
12 5% ALA on the right half of the face and a 
placebo gel on the left half twice daily for 3 
months 
Visible reduction in the depth of fine periorbital lines and fine vertical lines on 
the upper lip; deeper periorbital lines appeared shallow; increase in dermal 
density (ultrasound)
Hyaluronic acid (HA) 
Pavicic 
et al. [95]
R, DB, PC,  
RL 
76 HA cream 0.1% (w/w) (50, 130, 300, 800, and 
2,000 kDa, respectively) twice daily on periocular 
wrinkles for 60 days 
Significant improvement in skin hydration level; remarkable improvement in 
skin elasticity; significant reduction in wrinkle depth due to better penetration 
abilities of low-molecular-weight HA
Jegasothy 
et al. [96]
R, SB 33 Nano-hyaluronic acid in a cream, serum, and 
lotion; 8 weeks of treatment in the periorbital 
region 
Significant improvement in moisturizing effect of the product range and skin 
elasticity; skin roughness improved remarkably
Kaya 
et al. [21]
PC 6 P 
17 C 
Daily topical application to the forearm of a 
1% preparation of intermediate-size HA 
fragments for 1 month 
None of the control participants revealed a measurable increase in skin 
thickness; by contrast, all 6 patients with skin atrophy (either age-related or 
associated with corticosteroid therapy) developed marked skin thickening 




OL, PG 20 Four groups, each with a different anti-wrinkle 
cream containing HA (Balea, Nivea, Lancôme, 
Chanel), daily use, 3-month trial 
Significant reduction in perioral and orbital wrinkle depth and remarkable 
increase in skin tightness in all groups; minimal significant changes in skin 
elasticity in individual groups 
C, control participants; DB, double blind; n, number of participants; OL, open label; PC, placebo controlled; P, patients with atrophic skin lesions; PG, parallel group; R, 









































































excision repair and enhances repair of UVB radiation-
induced cyclobutane pyrimidine dimers and UVA radia-
tion-induced 8-oxo-7,8-dihydro-2′-deoxyguanosine. 
Multiple randomized, placebo-controlled trials have 
shown clinical improvement in skin texture, elasticity, 
and wrinkles after 12 weeks of daily application of cream 
containing 5% niacinamide [24–26]. However, clinical 
trials with more participants need to be conducted to de-
termine its applicability as a definitive treatment for pho-
toaging. 
L-Ascorbic Acid (Vitamin C)
Vitamin C, also known as ascorbic acid, plays a critical 
role in collagen and elastin synthesis as it is a cofactor for 
Table 3. Human studies on topical antioxidants [24–26, 29–33, 35, 36, 39]
Study Study design n Treatment arm(s) Efficacy
Niacinamide (B3)
Kawada 
et al. [24] 








R, DB, PC, RL 50 Moisturizer control product vs. the same 
moisturizer product containing 5% niacinamide 
for 12 weeks
Niacinamide significantly improved fine lines/wrinkles, hyperpigmentation 
spots, texture, and red blotchiness vs. control 
L-Ascorbic acid (vitamin C) 
Humbert 
et al. [33]
R, DB, PC 20 5% vitamin C cream vs. vehicle for 6 months Significant increase in the density of skin microrelief and a decrease in deep 
furrows; ultrastructural evidence of elastic tissue repair 
Nusgens 
et al. [29]
R, DB, PC, RL 10 5% L-ascorbic acid in glycerol vs. glycerol alone 
for 6 months daily (right vs. left arm)
Collagen type I and III mRNAs were increased to a similar extent by vitamin 
C in skin biopsies 
Raschke
et al. [30]
R, DB, PC, RL 23 3% vitamin C cream and placebo cream each on 
one half of the face (split-face design) twice daily 
for 12 weeks 
After 1 month, a significant increase in the number of dermal papillae was 
demonstrated by confocal laser scanning microscope; significant reduction in 




R, DB, PC, RL 10 Vitamin C complex having 10% ascorbic acid 
(water soluble) and 7% tetrahexyldecyl ascorbate 
(lipid soluble) in an anhydrous polysilicone gel 
base to one-half of the face and the inactive 
polysilicone gel base to the opposite side for 12 
weeks 
Biopsies showed increased grenz zone collagen, as well as increased staining 
for collagen type I mRNA; significant improvement in the vitamin C-treated 
side was seen in the decreased photoaging scores of the cheeks (p = 0.006) and 
peri-oral area (p = 0.01).
Haftek 
et al. [32] 
R, DB, RL 20 5% stabilized vitamin C and 0.1% madecassoside 
(Remederm) vs. Toleriane for 6 months twice 
daily half
Significant improvement in the clinical score for deep and superficial 
wrinkles, suppleness, firmness, roughness, and skin hydration; in 2/3 of the 





R, PC, DB, RL 9 15% vitamin C, 1% vitamin E, and ferulic acid 
and its vehicle vs. vehicle only were applied to 
separate patches of normal-appearing human 
skin for 4 days; each patch was irradiated with 
solar-simulated UV, 2–10 minimal erythema 
doses; 1 day later, the skin was evaluated for 
erythema and sunburn cells, and immuno-
histochemically for thymine dimers and p53 
Significant and meaningful photoprotection; 
particularly effective for reducing thymine dimer mutations known to be 





  Aliquots of vehicle; 0.5% trans-ferulic acid; 15% 
L-ascorbic acid, 1% DL-α-tocopherol, and 15% 
L-ascorbic acid, 1% DL-α-tocopherol, and 0.5% 
trans-ferulic acid were applied to patches of back 
skin daily for 4 days; a 1,000-W solar simulator 
delivered UV radiation to the skin surface; 
evaluation was carried out 24 h later 
Doubled photoprotection to solar-simulated skin irradiation from 4- to 
approximately 8-fold measured by both erythema and sunburn cell formation; 




et al. [39] 
R, DB, PC 31 f 1% CoQ10 cream or placebo cream twice daily 
for 3 months
Reduction in the wrinkle score in the 1% CoQ10 group after 5 months vs. no 
reduction in the control 
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both prolyl and lysyl hydroxylases, which catalyze the for-
mation of hydroxyproline and hydroxylysine [27]. The 
hydroxylation of proline and lysine facilitates the excre-
tion of procollagen from fibroblasts. Its effect as antioxi-
dant in the skin is based on the modulation of the UV-
induced ROS damage [28]. 
Effectiveness of vitamin C in concentrations of up to 
15% was shown in several double-blind, placebo-con-
trolled studies [29–33]. The increase in collagens I and III 
was also observed histologically after use of vitamin C 
[29]. However, the clinical studies conducted so far in-
cluded low participant numbers; thus, placebo-controlled 
trials with higher numbers of participants are necessary 
to confirm the promising clinical results seen in earlier 
studies. 
Ascorbic acid requires an acidic environment for op-
timal absorption and oxidizes very quickly when exposed 
to light and air. This problem has been partially overcome 
by chemically modifying ascorbic acid by esterification of 
its hydroxyl group. 
D-α-Tocopherol (Vitamin E)
D-α-Tocopherol is the synthetic form of vitamin E 
which is found in commercial preparations. It acts as an-
tioxidant within cell membranes where it protects poly-
unsaturated fatty acids from free radicals. Vitamin E also 
works as a direct antioxidant by donating electrons to sin-
glet oxygen and superoxide anions. Ascorbic acid and 
glutathione are both essential for the sustained action of 
vitamin E as they donate necessary hydrogen ions when 
the tocopherol radical is formed. In vitro experiments 
have shown a reduction in MMP-1 transcription after 
fibroblasts from older individuals were incubated with 
D-α-tocopherol. MMP-1 is normally elevated in older 
persons compared with younger individuals [34]. In-
crease in MMP-1 levels leads to collagen breakdown and 
the destruction of supportive matrix [4]. In vivo, vitamin 
E has been studied as a sun protectant [35, 36]. Pretreat-
ment of hairless mice skin with 5% tocopherol before 
UVB exposure resulted in a 75% decrease in the severity 
of skin wrinkling and a significant decrease in skin tumor 
formation [37]. 
As ascorbic acid is needed to maintain active vitamin 
E stores, the combined effect of vitamins C and E has also 
been studied. The topical use of vitamins C and E com-
bined before UV irradiation decreased erythema, cyto-
kine production, thymine dimer formation, and p53 up-
regulation [35]. Additionally, it was shown that ferulic 
acid (a botanical agent) could reduce the oxidative stress 
4-fold when added to formulations containing vitamins 
C and E [36]. Data supporting any effect of vitamin E in 
topical therapies by improvements in skin wrinkling, dis-
coloration, or texture, however, are still lacking. 
Coenzyme Q10
Coenzyme Q (CoQ10) was discovered in 1957 by Fred-
erick Crane. The name coenzyme Q10 derives from its 
chemical structure, a benzoquinone ring with a side chain 
composed of 10 isoprene units. The structure is similar to 
some vitamins (e.g., vitamin K); however, CoQ10 is not a 
vitamin since it is synthesized in the body, whereas vita-
mins must be obtained from the diet. 
It has a fundamental role in cellular bioenergetics as a 
cofactor for mitochondrial enzyme complexes involved 
in the oxidative phosphorylation and production of ade-
nosine triphosphate (ATP). Beside this, CoQ10 serves as 
an antioxidant or free radical scavenger, and is able to 
stimulate collagen production [38]. Its application in dif-
ferent illnesses is being discussed but not yet established. 
So far, one placebo-controlled double-blind study could 
show wrinkle improvement after application of 1% CoQ10 
cream [39]. Furthermore, it was shown in vitro that it re-
duces MMP activity [39]. 
Plant-Based Ingredients
Phenols
Phenols are aromatic organic compounds found in 
many plants (e.g., black, white, or green tea, soja, grapes, 
and berries). The naturally occurring phenols are referred 
to as flavonoids and procyanides. Several studies have 
shown the antioxidant activity of phenols, which is asso-
ciated with their chemical structure [40]. Thring et al. 
[41] assessed 23 plant extracts for their antiaging proper-
ties as anti-elastase and anti-collagenase activities, and 
antioxidant activity along with their phenolic content. 
The white tea showed the highest anti-elastase and anti-
collagenase activities as well as the highest antioxidant 
activity and phenolic content. Elmets et al. [42] demon-
strated in an in vivo study that the topical application of 
green tea extracts results in a dose-dependent inhibition 
of the erythema response evoked by UV radiation. Histo-
logically, skin treated with green tea extracts reduced the 
number of sunburn cells and protected epidermal Lang-
erhans cells from UV damage. Few randomized placebo-
controlled clinical trials with green tea extracts (listed in 
Table 4) have shown improvement in elastin content on 
skin biopsies and improvement in skin texture [43]. 
Mohammad et al. [44] showed in a preliminary ex-
periment that Prosopis cineraria bark extract has a sig-









































































study with 9 volunteers, they measured an increase in hy-
dration and elasticity compared to the base formulation. 
Resveratrol, which is also a phenol, is another promis-
ing active ingredient. It is contained in various plants (in-
cluding grapes, grapefruits, and nuts). Just like a low-cal-
orie diet, resveratrol promotes the expression of sirtuin 
genes, leading to longer cell survival [45]. Resveratrol ef-
fectively prevented UVB-induced skin edema in a pre-
clinical study [46]. 
Another important active ingredient of the phenol 
family is ferulic acid (4-hydroxy-3-methoxycinnamic 
acid), which is widely present in the cell walls of numer-
ous plants, including fruits, vegetables, and grains [47, 
48]. Today, it is mainly used as a photoprotective agent in 
skin products. Its photoprotective effect has been demon-
strated in several studies [35, 49, 50]. The synergistic ef-
fect of ferulic acid with vitamins C, E, and β-carotene is 
another promising and interesting aspect [35, 50]. Lin et 
al. [36] demonstrated that the addition of ferulic acid to a 
solution containing vitamins C and E doubled the skin-
protective capacity of the formulation, from 4- to 8-fold.
Ectoine
Ectoine is an organic molecule of low molecular weight 
occurring in halophilic bacteria [51]. These bacteria grow 
under extreme conditions (dryness, high temperatures, 
and intensive UV irradiation) and protect themselves 
against these stressors by synthesizing ectoine. 
Pretreatment with ectoine before sun exposure pre-
vents the UV-induced reduction in Langerhans cells [52]. 
Furthermore, it was shown that ectoine protects the skin 
from the effects of UVA-induced cell damage in different 
ways; it prevents the formation of ceramide by singlet-
oxygen-quenching properties, and it prevents mutations 
Table 4. Human studies on plant-based ingredients [35, 42–44, 50, 98, 99]






6 Areas of normal skin were treated with an 
extract of green tea; 30 min later, the treated sites 
were exposed to 2-MED solar-simulated 
radiation; UV-treated skin was examined 
clinically for UV-induced erythema, 
histologically for the presence of sunburn cell or 
Langerhans cell distribution 
Dose-dependent inhibition of the erythema response evoked by UV radiation; 
on histologic examination, skin treated with green tea extract reduced the 




R, DB, PC 40 Combination regimen of 10% green tea cream 
and 300 mg green tea oral supplementation 
twice daily vs. a placebo regimen for 8 weeks 
No significant differences were noted between groups on any of the 
dermatologist-rated parameters; significantly greater improvement in elastin 
content of skin biopsies in the treatment group compared with controls (p < 
0.05) 
Syed [98, P25] R, DB, PC 60 2% epigallocatechin gallate (found in green tea) 
in a hydrophilic gel vs. placebo gel b.i.d. for 4 
weeks 
Marked improvement in skin texture noted in 46.7% of subjects: 83.3% of 
experimental group and 10.0% of the control group improved 
2% Prosopis cineraria bark
Mohammad 
et al. [44]
R, SB, PC, RL 9 2% Prosopis cineraria bark extract loaded 
emulsion formulation vs. base formulation 
applied for 8 weeks 
The formulation decreased the skin melanin, erythema, and sebum contents 




R, PC, RL 9 Solution of 15% L-ascorbic acid, 1% DL-α- 
tocopherol, and 0.5% trans ferulic acid (CEF) vs. 
vehicle only applied daily for 4 days to separate 
patches; on day 4 skin irradiation with solar-
simulated UV radiation
CEF provided substantial protection against UV-induced erythema, apoptosis, 
and DNA mutation vs. vehicle-treated skin 
Salja 
et al. [99]
PG 6 Caffeic or ferulic acid solution immediately 
applied to UV-B irradiated sites on the forearm 
Caffeic acid and ferulic acid proved a significant protection to the skin against 
UVB-induced erythema vs. controls
Oresajo 
et al. [50]
PG, PC 10 Vitamin C, ferulic acid, and phloretin 
(CFerPhlor) or vehicle alone (control) were 
applied to back skin daily for 4 days; skin was 
irradiated with solar-simulated UV 1–5 times 
MED 
CferPhlor-treated site showed statistically significant reduction in
erythema compared to the vehicle-treated control site (*p < 0.01) at all MEDs 
tested 
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in the mitochondrial DNA in dermal fibroblasts [53]. In 
an in vivo study with 104 volunteers, Heinrich et al. [54] 
demonstrated that a formulation containing 2% ectoine 
was more effective in terms of skin hydration, skin elastic-
ity, and skin surface structure than vehicle-only treat-
ment.
Bioactive Peptides
Peptides are formed from short amino acid sequences 
and confer a diverse range of biological effects [55]. Ac-
tive sequences of these peptides can be isolated and syn-
thetically modified to further enhance their biological ac-
tivities [56]. 
Along with health benefits demonstrated in areas such 
as inflammation, wound healing, angiogenesis, and anti-
microbial defense, bioactive peptides are also being ex-
plored for their use in cosmeceuticals [56]. 
These topical peptides can be categorized into 4 groups:
 − signal peptides;
 − carrier peptides;
 − neurotransmitter inhibitor peptides; and 
 − enzyme inhibitor peptides
The first 3 groups have the most data on skin rejuvena-
tion (Table 5). The peptides with the highest evidence are 
explained in more detail below.
Table 5. Human studies on peptides [58–61, 68–73]
Peptide Study Study design n Treatment arm(s) Efficacy








R, DB, PC, RL 93 Pal-KTTKS O/W moisturizer vs. placebo 
O/W moisturizer for 12 weeks






16 pal-KTTS vs. retinol Similar wrinkle reduction and increase in skin thickness in 
both groups 
Fu [60] R, PG 196 5% niacinamide, pal-KTTS, antioxidant, 
retinyl propionate vs. 0.02% tretinoin for 8 
weeks 






et al. {61] 
R, DB, PC 10 GEGK vs. placebo cream for 8 weeks Histochemical analyses indicate increased formation of 
procollagen, hyaluronic acid, and fibronectin; significant 
improvement in skin physiological and clinical parameters 
such as skin wrinkles and skin roughness 
Farwick 
et al. [61] 
R, DB, PC 30 GEGK vs. placebo-cream for 8 weeks Improvement in skin physiological and clinical parameters 
such as skin wrinkles and skin roughness 







R, DB, PG, PC 67 GHK-Cu vs. placebo creams Significant improvement in skin laxity and clarity with 
decreased wrinkles 
Leyden J
et al. [69, P69]
R, DB, PC 41 GHK-Cu vs. placebo and vitamin K cream 
around the eyes
Reduction in lines and wrinkles, increase in skin density and 
thickness around the eyes
Leyden 
et al. [69, P68] 





20 Topical tretinoin, topical vitamin C, topical 
GHK-Cu, topical melatonin; application on 
thigh skin for 12 weeks
Increase in procollagen synthesis: 4/10, 5/10, 5/10, and 7/10 
of patients showed response to tretinoin, vitamin C, 
melatonin, and GHK-Cu, respectively 










R, PG 24 Acetyl hexapeptide-3 with tripeptide-10 
citrulline (group G1), tripeptide-10 citrulline 
(group, G2), acetyl hexapeptide-3 (group G3), 
or neither peptide (group G4) for 60 days 
Significant reduction in wrinkles (up to 30%)
Blanes-Mira 
et al. [70]
PC, OL 10 O/W emulsion containing 10% acetyl 
hexapeptide-3 solution vs. placebo creams for 
30 days 




R, DB, PC, PG 60 Acetyl hexapeptide-3 vs. placebo at a 3:1 ratio 
twice daily for 4 weeks 
Significant reduction in depth of wrinkles
AC, active controlled; DB, double-blind; n, number of participants; OL, open label; PC, placebo controlled; PG, parallel group; R, randomized; RL, right-left compari-









































































Signal peptides increase matrix cell activities and stim-
ulate protein production in general and collagen synthe-
sis in specific. Substances with most existing data are the 
procollagen-I-derived pentamer lysine-threonine-threo-
nine-lysine-serine (KTTS), which stimulates the produc-
tion of collagens I and III and fibronectin in vitro in a 
time- and dose-dependent manner, and the copper tri-
peptide glycil-L-histidyl-L-lysine (GHK) [57]. The latter 
also acts as a carrier peptide. 
To overcome permeability issues, palmitoyl is added 
to the peptide fragments. 
Several clinical published studies have shown that top-
ical formulations containing palmitoyl-KTTS have the 
capacity to reduce fine lines, wrinkles, and improve skin 
texture significantly [58, 59]. However, most of reported 
clinical benefits were obtained by using a formulation 
containing palmitoyl-KTTKS and other active ingredi-
ents (e.g., niacinamide and vitamin E), or at least in the 
presence of a basic moisturizer, suggesting that the ob-
served benefits may not be solely produced by the conju-
gated peptide. Furthermore, study design and data evalu-
ation are not described in detail in all studies, except for 
the studies by Robinson et al. [58] and Fu et al. [60]. 
A more recent signal peptide is the tetrapeptide GEKG 
(Gly-Glu-Lys-Gly), represented as a sequence in several 
extracellular matrix proteins. When applied to human 
dermal fibroblasts in vitro, the peptide caused up-regula-
tion of fibronectin, HA synthase, and pro-collagen I 
mRNA [61]. Tested topically on 10 persons in a double-
blind, randomized, placebo-controlled trial over 8 weeks, 
GEKG led to increased levels of collagen I mRNA and 
increased formation of procollagen I, HA, and fibronec-
tin. Significant improvements in the elasticity of skin 
(measured by resilient distension) were claimed in fur-
ther clinical studies [61].
The tripeptide-1 glycyl-L-histidyl-L-lysine (GHK) is 
primarily known as carrier peptide. This kind of peptide 
facilitates the transportation of important substances. 
The major application of GHK is to deliver important 
trace elements [62]. GHK is a fragment of the α2-chain of 
collagen I and exhibits a high affinity for copper (I) ions, 
forming spontaneously a tripeptide-copper complex 
(GHK-Cu) [63, 64]. 
Originally, GHK-Cu was studied in the skin for its 
ability to promote wound healing [65, 66]. It was further 
shown to be able to restore the function of irradiated fi-
broblasts. Consequently, it also has to have effects on 
DNA repair [67]. A few placebo-controlled clinical stud-
ies claimed GHK-Cu improves skin quality in women 
[68, 69].
Neurotransmitter inhibitor peptides mimic the action 
of botulinum toxin by emulating the amino acid sequence 
of the synaptic protein, SNAP-25. They inhibit acetylcho-
line release at the neuromuscular junction and have cu-
rare-like effects [62].
Acetyl hexapeptide-3 is one of the best-studied pep-
tides in this group. A clinical vehicle-controlled study by 
Blanes-Mira et al. [70] showed that 10% acetyl hexapep-
tide-3 reduced the depth of periorbital wrinkles up to 
30% (vs. 10%) after 30 days of use. A more recent pro-
spective, randomized, controlled study on 24 female vol-
unteers with a mean age of 45 years found similar results 
[71]. Yet, these results should be interpreted with caution 
due to the small number of patients per group. In an-
other randomized trial, acetyl hexapeptide-3 or placebo 
was applied to periorbital wrinkles of 60 Chinese subjects 
twice daily for 4 weeks. In the objective evaluation, sili-
cone replicas of the skin at the application area were 
made before and after the treatment, which were ana-
lyzed by a wrinkle analysis apparatus. Analysis showed a 
significant reduction in the depth of wrinkles in the treat-
ment arm [72]. 
Combinations
Recent studies suggest that the combination of anti-
oxidants and cell regulators may multiply the antiaging 
effects. Fu et al. [60] compared the combination of nia-
cinamide/pentapeptide/retinyl propionate to a formula-
tion with 0.02% retinoic acid in a vehicle-controlled, ran-
domized, in vivo study with 196 patients. The combina-
tion of niacinamide/pentapeptide/retinyl propionate led 
to a significant reduction in wrinkles after 8 weeks, where-
as similar results with the retinoic acid formulation could 
only be achieved after 24 weeks. 
Conclusion
Cosmetic products with targeted ingredients are in-
creasingly used to prevent skin aging and to maintain re-
sults after skin rejuvenation procedures. Meanwhile, 
there is a large number of products, marketed as cosme-
ceuticals, which claim that their ingredients actively im-
prove skin health and have rejuvenation capabilities. 
However, most products available on the market lack ev-
idence of clinical benefits from use of sufficiently high 
concentrations of these ingredients. Additionally, clinical 
trial data for their clinical efficacy are meagre due to var-
ious factors including permeability with regard to the 







































































Over-the-Counter Antiaging Agents 11Dermatology
DOI: 10.1159/000509296
The best evidence (level A, randomized, double-blind, 
placebo-controlled studies) for the effectiveness of active 
substances in local therapeutics so far is available for vi-
tamins B3, C, and A, and their derivatives; as well as for 
various α-hydroxy acids such as glycolic or α-lipoic acid. 
Furthermore, some peptides are relatively well investigat-
ed. Several scientific studies indicate that palmitoyl-KTTS 
has a capacity to significantly reduce signs of skin aging 
on the face [58–60]. In vivo synergistic activity of cell reg-
ulators and antioxidants, as observed in some studies [60, 
73], makes the combination of differently acting active 
substances promising for cosmetic and dermatological 
applications.
A major shortcoming in published studies is that most 
industry-driven studies do not meet the standards re-
quired for a scientific publication yet. Placebo-controlled, 
double-blind studies, the standard in medical research, 
are still too rare for cosmetic products. Most of the exist-
ing scientific investigations were carried out on very small 
number of subjects, mainly female volunteers, with a 
wide age range. Good clinical practice was often lacking 
in the protocols. 
The product manufacturers and universities ought to 
work together in this field and generate more data on 
safety and efficacy, with the aim of improving the benefit 
for patients.
Qualitatively, evidenced studies would also justify 
high market prices for well-studied cosmetic products.
Key Message
Scientific evidence is still scarce for many topical antiaging 
products. 
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